Oncology Institute, Inc. TOI
We take great care to ensure that the data presented and summarized in this overview for Oncology Institute, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TOI
View all-
Deerfield Management Company, L.P. (Series C) New York, NY3.36MShares$10.1 Million0.1% of portfolio
-
Tiff Advisory Services Inc2.98MShares$9 Million0.81% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.15MShares$6.48 Million0.0% of portfolio
-
Josh Arnold Investment Consultant, LLC Edina, MN1.99MShares$6.01 Million1.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$5.29 Million0.0% of portfolio
-
Kent Lake Capital LLC Mill Valley, CA1.75MShares$5.29 Million0.37% of portfolio
-
Cincinnati Insurance CO1.24MShares$3.75 Million0.03% of portfolio
-
Free Gulliver LLC New Orleans, LA544KShares$1.64 Million0.31% of portfolio
-
Geode Capital Management, LLC Boston, MA386KShares$1.16 Million0.0% of portfolio
-
Manatuck Hill Partners, LLC Westport, CT350KShares$1.06 Million0.2% of portfolio
Latest Institutional Activity in TOI
Top Purchases
Top Sells
About TOI
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Insider Transactions at TOI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2025
|
Yale Podnos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
157,088
+39.95%
|
-
|
|
Mar 31
2025
|
Robert Ross Carter Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
197,368
+45.46%
|
-
|
|
Mar 31
2025
|
Jeremy Castle Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
162,281
+39.11%
|
-
|
|
Mar 31
2025
|
Daniel Virnich Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,083,334
+37.47%
|
-
|
|
Mar 26
2025
|
M33 Growth I L.P. Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,716,898
+14.2%
|
$2,716,898
$1.04 P/Share
|
|
Mar 26
2025
|
Daniel Virnich Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
22,640
+3.03%
|
$22,640
$1.04 P/Share
|
|
Mar 26
2025
|
Yale Podnos Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
9,056
+10.28%
|
$9,056
$1.04 P/Share
|
|
Mar 26
2025
|
Mark L Pacala Director |
BUY
Open market or private purchase
|
Indirect |
90,562
+28.7%
|
$90,562
$1.04 P/Share
|
|
Mar 26
2025
|
Brad Hively Director |
BUY
Open market or private purchase
|
Direct |
9,056
+1.32%
|
$9,056
$1.04 P/Share
|
|
Mar 26
2025
|
Karen Marie Johnson Director |
BUY
Open market or private purchase
|
Direct |
36,224
+15.12%
|
$36,224
$1.04 P/Share
|
|
Mar 26
2025
|
Jeremy Castle Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
9,056
+9.11%
|
$9,056
$1.04 P/Share
|
|
Mar 26
2025
|
Richard A Barasch Director |
BUY
Open market or private purchase
|
Indirect |
1,358,448
+43.34%
|
$1,358,448
$1.04 P/Share
|
|
Mar 26
2025
|
Robert Ross Carter Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
9,056
+18.69%
|
$9,056
$1.04 P/Share
|
|
Mar 19
2025
|
Daniel Virnich Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,261
-1.44%
|
$0
$0.89 P/Share
|
|
Mar 19
2025
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,150
-3.65%
|
$0
$0.89 P/Share
|
|
Mar 19
2025
|
Yale Podnos Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,975
-4.08%
|
$0
$0.89 P/Share
|
|
Jan 06
2025
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
258
-0.81%
|
$0
$0.34 P/Share
|
|
Dec 03
2024
|
Jeremy Castle Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,130
-1.37%
|
$0
$0.16 P/Share
|
|
Dec 02
2024
|
Brad Hively Director |
BUY
Open market or private purchase
|
Direct |
50,000
+6.98%
|
$0
$0.15 P/Share
|
|
Nov 26
2024
|
Brad Hively Director |
BUY
Open market or private purchase
|
Direct |
250,000
+28.84%
|
$0
$0.17 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 4.69M shares |
|---|---|
| Open market or private purchase | 1.84M shares |
| Other acquisition or disposition | 17M shares |
|---|---|
| Sale (or disposition) back to the issuer | 66.4K shares |